Your browser doesn't support javascript.
loading
Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss About.
Ma, Lucy X; Panov, Elan D; Allen, Michael J; Darling, Gail E; Yeung, Jonathan C; Swallow, Carol J; Brar, Savtaj S; Wong, Rebecca K; Veit-Haibach, Patrick; Kalimuthu, Sangeetha N; Chen, Eric X; Jang, Raymond W; Elimova, Elena.
Afiliação
  • Ma LX; 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre.
  • Panov ED; 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre.
  • Allen MJ; 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre.
  • Darling GE; 2Division of Thoracic Surgery, Department of Surgery, Toronto General Hospital.
  • Yeung JC; 2Division of Thoracic Surgery, Department of Surgery, Toronto General Hospital.
  • Swallow CJ; 3Department of Surgical Oncology, Princess Margaret Cancer Centre.
  • Brar SS; 3Department of Surgical Oncology, Princess Margaret Cancer Centre.
  • Wong RK; 4Department of Radiation Oncology, Princess Margaret Cancer Centre; and.
  • Veit-Haibach P; 5Joint Department Medical Imaging, and.
  • Kalimuthu SN; 6Department of Pathology, Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, Canada.
  • Chen EX; 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre.
  • Jang RW; 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre.
  • Elimova E; 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre.
J Natl Compr Canc Netw ; 20(2): 193-202, 2022 02.
Article em En | MEDLINE | ID: mdl-35130503
Gastroesophageal cancers carry poor prognoses, and are a leading cause of cancer-related morbidity and mortality worldwide. Even in those with resectable disease, more than half of patients treated with surgery alone experience disease recurrence. Multimodality approaches using preoperative and postoperative chemotherapy and/or radiotherapy have been established, resulting in incremental improvements in outcomes. Globally, there is no standardized approach, and treatment varies with geographic location. The question remains of how to select the optimal perioperative treatment that will maximize benefit for patients while avoiding toxicities from unnecessary therapies. This article reviews currently available evidence supporting preoperative and postoperative therapy in gastroesophageal cancers, with an emphasis on recent practice-changing trials and ongoing areas of investigation, including the role of immune checkpoint inhibition and biomarker-guided treatment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article